author-photo

Ellis G. Levine

Roswell Park Cancer Institute

96

Papers

3772

Citations

Citation Trend

Filter By

Papers (71) Sort By

Journal Conference Others

Sociodemographic Factors Associated With Rapid Relapse in Triple-Negative Breast Cancer: A Multi-Institution Study

2021 Journal of The National Comprehensive Cancer Network
Show All
- Source
- Cite
- Save
Citations (3)
MammaPrint Guides Treatment Decisions in Breast Cancer: Results of the IMPACt Trial

2020 BMC Cancer
Show All
- Source
- Cite
- Save
Citations (12)
Abstract P5-07-02: Factors associated with rapid relapse in triple negative breast cancer: A multi-institution study

2020 Cancer Research
Show All
- Source
- Cite
- Save
Citations (2)
320 Phase IIa study of alpha-DC1 vaccine against HER2/HER3, chemokine modulation regimen and pembrolizumab in patients with asymptomatic brain metastasis from triple negative or HER2+ breast cancer

2020 Journal for ImmunoTherapy of Cancer
Show All
- Source
- Cite
- Save
Citations (0)
Abstract P2-14-11: Treatment recommendations in ER+ patients ≤ 50 years: Comparison of the 21-gene assay and 70-gene signature in the PROMIS study

2020 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
321 Phase I clinical trial assessing the combination of systemic chemokine modulatory regimen targeting TLR3 with neoadjuvant chemotherapy in triple negative breast cancer

2020 Journal for ImmunoTherapy of Cancer
Show All
- Source
- Cite
- Save
Citations (0)
A phase Ib trial of enzalutamide with venetoclax in metastatic castration-resistant prostate cancer (mCRPC).

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Outcome of Everolimus-Based Therapy in Hormone-Receptor-Positive Metastatic Breast Cancer Patients After Progression on Palbociclib:

2020
Show All
- Source
- Cite
- Save
Citations (8)
Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology

2019 Journal of The National Comprehensive Cancer Network
Show All
- Source
- Cite
- Save
Citations (197)
A phase I/II trial of pazopanib alternating with bevacizumab in treatment-naïve metastatic clear cell renal cell carcinoma (CCRCC) patients: Phase I results.

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)